The researchers from Sao Paulo State University and the US Horticultural Research Laboratory associated the citrus flavonoid with a significant reduction in levels of cholesterols and triglycerides which are markers of insulin resistance at low (10 and 25 mg/kg BW) and high ( 100 mg/kg BW) doses, with the best results being observed at 25 mg per kg of body weight.
The study authors wrote, “Therefore, our results showed that low doses of dietary eriocitrin are able to counteract the deleterious effects of high-fat diet and prevent risk factors of metabolic syndrome and chronic disease related to obesity.”
“Further, the use of lower doses may help to prevent unintended complications possibly occurring at much higher doses of potent antioxidant supplements such as eriocitrin.”
“As a leading supplier of citrus flavonoids, we put great importance into the continual development of research into these powerful ingredients,” said Rob Brewster who is the President of Ingredients by Nature (IBN). “Eriocitrin is not as commonly recognized as other fruit-derived flavonoids, but the science shows that it is a potent source of health support for a variety of health complications. We look forward to seeing what future research will continue to reveal about it.”
During this study 40 male mice were fed a high-fat diet for 4 weeks to induce obesity, then they were divided at random into four different groups for an additional 4 weeks and given doses of eriocitrin at 0, 10, 25, or 100 mg per kg of body weight, while a control group was fed a standard diet for the 8 weeks.
The researchers reported the best results being observed in the eriocitrin group taking 25 mg/kg with reductions in triglycerides of 31%, total cholesterol of 6%, and liver triacylglycerols of 28% compared to the control group. Eriocitrin at 25 mg/kg was associated with a reduction in lipid peroxidation of 19%, and markers of insulin resistance including resistin and the insulin resistance index also significantly decreased. Additionally, serum glucose levels also significantly decreased by 25%, insulin levels by 35% in this same group.
“Most studies on eriocitrin haven’t explored its effect on obesity induces metabolic disturbances and, because the global rate of obesity continues to increase, we felt that it was important to examine the topic further,” said the corresponding author Dr. Thais Cesar who is also an associate professor of nutrition at Sao Paulo State University. “Eriocitrin significantly improved metabolic, inflammatory, and oxidative stress parameters across multiple biomarkers, showing potential to delay the development of inflammatory complications. We look forward to performing additional research on eriocitrin in the future.”
This study was sponsored by IBM, and also showed that eriocitrin was effective in terms of glucose and lipid metabolism, especially with blood glucose reduction, along with delivering a strong antioxidant defense by directly helping the uptake of oxygen radicals and promoting the activation of endogenous defense mechanisms. This effect has been reported in previous studies including with the lemon flavonoid blend Eriomin, which is made up primarily of eriocitrin. Last year, the company also received patent approval from the USPTO for IBN’s use of eriocitrin as a method of reducing blood glucose levels.
